Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Compare the rate of treatment failure in osteopetrosis patients receiving interferon gamma in combination with calcitriol to the rate of treatment failure in patients receiving calcitriol alone.

II. Compare the number of adverse events or clinical manifestations of disease progression occurring in these patients.

III. Assess the effects of interferon gamma on hematopoiesis, cranial nerve function, and rate of infection in these patients.


Clinical Trial Description

PROTOCOL OUTLINE: This is a randomized, placebo controlled, open label study. Patients are randomized to one of two arms (interferon gamma in combination with calcitriol or calcitriol alone).

Arm I: Patients receive calcitriol once daily. Interferon gamma is administered by subcutaneous injection three times a week.

Arm II: Patients receive calcitriol once daily. Patients may continue treatment in the absence of toxicity and disease progression. If disease progression is diagnosed in the control group, patients will then receive interferon gamma in combination with calcitriol.

Patients are followed every 4 weeks. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00004402
Study type Interventional
Source FDA Office of Orphan Products Development
Contact
Status Completed
Phase Phase 3
Start date November 1999
Completion date June 2000

See also
  Status Clinical Trial Phase
Recruiting NCT01087398 - Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Phase 2/Phase 3
Terminated NCT00638820 - Reduced Intensity AlloTransplant For Osteopetrosis Phase 2
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Terminated NCT00145587 - Stem Cell Transplantation for Children Affected With Osteopetrosis N/A
Completed NCT01199094 - Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5 N/A
Completed NCT00043329 - Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis Phase 4
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Completed NCT02666768 - ACTIMMUNE in Intermediate Osteopetrosis Phase 2
Terminated NCT00145886 - rhPTH Therapy for Low Turnover Bone Fragility Phase 1
Terminated NCT00968864 - T-cell Depleted Alternative Donor Transplantation Phase 2
Completed NCT00730314 - Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Phase 1/Phase 2
Active, not recruiting NCT03301168 - Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant Phase 1/Phase 2
Terminated NCT02065869 - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant Phase 1/Phase 2
No longer available NCT01200017 - Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant